116 related articles for article (PubMed ID: 37055337)
1. Factors Associated With Receipt of Molecular Testing and its Impact on Time to Initial Systemic Therapy in Metastatic Non-Small Cell Lung Cancer.
Osazuwa-Peters OL; Wilson LE; Check DK; Roberts MC; Srinivasan S; Clark AG; Crawford J; Chrischilles E; Carnahan RM; Campbell WS; Cowell LG; Greenlee R; Abbott AM; Mosa ASM; Mandhadi V; Stoddard A; Dinan MA
Clin Lung Cancer; 2023 Jun; 24(4):305-312. PubMed ID: 37055337
[TBL] [Abstract][Full Text] [Related]
2. Biomarker Testing, Treatment, and Outcomes in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Using a Real-World Database.
Bhandari NR; Hess LM; He D; Peterson P
J Natl Compr Canc Netw; 2023 Sep; 21(9):934-944.e1. PubMed ID: 37673115
[TBL] [Abstract][Full Text] [Related]
3. Molecular testing patterns in metastatic non-small cell lung cancer.
MacLean E; Louder A; Saverno K; Smith G; Mardekian J; Brunis C; Ward M; Sweetman R; Pasquale M
Am J Manag Care; 2016 Feb; 22(2):e60-7. PubMed ID: 26881321
[TBL] [Abstract][Full Text] [Related]
4. Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting.
Sireci AN; Krein PM; Hess LM; Khan T; Willey J; Ayars M; Deyoung K; Bhaskar S; Mumuney G; Coutinho A
Clin Lung Cancer; 2023 Jul; 24(5):429-436. PubMed ID: 37080814
[TBL] [Abstract][Full Text] [Related]
5. Disparities and Trends in Genetic Testing and Erlotinib Treatment among Metastatic Non-Small Cell Lung Cancer Patients.
Palazzo LL; Sheehan DF; Tramontano AC; Kong CY
Cancer Epidemiol Biomarkers Prev; 2019 May; 28(5):926-934. PubMed ID: 30787053
[TBL] [Abstract][Full Text] [Related]
6. Practice-Level Variation in Molecular Testing and Use of Targeted Therapy for Patients With Non-Small Cell Lung Cancer and Colorectal Cancer.
Roberts TJ; Kehl KL; Brooks GA; Sholl L; Wright AA; Landrum MB; Keating NL
JAMA Netw Open; 2023 Apr; 6(4):e2310809. PubMed ID: 37115543
[TBL] [Abstract][Full Text] [Related]
7. Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens.
Waliany S; Wakelee H; Ramchandran K; Das M; Huang J; Myall N; Li C; Pagtama J; Tisch AH; Neal JW
Clin Lung Cancer; 2022 Sep; 23(6):498-509. PubMed ID: 35753988
[TBL] [Abstract][Full Text] [Related]
8. Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small-Cell Lung Cancer Patients Treated in the Community Practice Setting.
Nadler E; Espirito JL; Pavilack M; Boyd M; Vergara-Silva A; Fernandes A
Clin Lung Cancer; 2018 Jul; 19(4):360-370. PubMed ID: 29576407
[TBL] [Abstract][Full Text] [Related]
9. Interventional pulmonology use of cell-free DNA assay for metastatic non-small cell lung cancer: the UC Davis experience.
Phan C; Jespersen F; Weipert C; Li T; Yoneda KY
Ther Adv Respir Dis; 2022; 16():17534666221135324. PubMed ID: 36346075
[TBL] [Abstract][Full Text] [Related]
10. Real-World Molecular Testing and Treatment Patterns in Brazilian Patients with Newly Diagnosed Locally Advanced or Metastatic NSCLC.
Cronemberger E; Baldotto C; Marinho F; De Marchi P; Araújo LH; Franke F; Salles P; Calabrich A; Almeida T; Custodio MG; Maria AS; Pereira MH; Castro G
Clinics (Sao Paulo); 2020; 75():e1777. PubMed ID: 33084767
[TBL] [Abstract][Full Text] [Related]
11. Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network.
Robert NJ; Espirito JL; Chen L; Nwokeji E; Karhade M; Evangelist M; Spira A; Neubauer M; Bullock S; Walberg J; Cheng SK; Coleman RL
Lung Cancer; 2022 Apr; 166():197-204. PubMed ID: 35313244
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy Utilization Among Patients With Metastatic NSCLC: Impact of Comorbidities.
Zhang D; Tailor TD; Kim C; Atkins MB; Braithwaite D; Akinyemiju T
J Immunother; 2021 Jun; 44(5):198-203. PubMed ID: 33758148
[TBL] [Abstract][Full Text] [Related]
13. Utilization Patterns and Trends in Epidermal Growth Factor Receptor (EGFR) Mutation Testing Among Patients With Newly Diagnosed Metastatic Lung Cancer.
Shen C; Kehl KL; Zhao B; Simon GR; Zhou S; Giordano SH
Clin Lung Cancer; 2017 Jul; 18(4):e233-e241. PubMed ID: 28024927
[TBL] [Abstract][Full Text] [Related]
14. Real-world outcomes among patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first-line setting.
Apple J; Shenolikar R; De Silva K; Sun P; Spira A
Cancer Med; 2023 Jun; 12(12):13415-13425. PubMed ID: 37306623
[TBL] [Abstract][Full Text] [Related]
15. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting.
Presley CJ; Tang D; Soulos PR; Chiang AC; Longtine JA; Adelson KB; Herbst RS; Zhu W; Nussbaum NC; Sorg RA; Agarwala V; Abernethy AP; Gross CP
JAMA; 2018 Aug; 320(5):469-477. PubMed ID: 30088010
[TBL] [Abstract][Full Text] [Related]
16. Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers.
Karve SJ; Price GL; Davis KL; Pohl GM; Smyth EN; Bowman L
BMC Health Serv Res; 2014 Nov; 14():555. PubMed ID: 25392276
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a 'Watch and Wait' Approach for Chemotherapy in Patients with Newly Diagnosed Advanced Non-small Cell Lung Cancer from a Diverse Community Population.
Noonan K; Tong KM; Laskin J; Zheng YY; Melosky B; Sun S; Murray N; Ho C
Clin Oncol (R Coll Radiol); 2015 Sep; 27(9):505-13. PubMed ID: 26095646
[TBL] [Abstract][Full Text] [Related]
18. Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network.
Nadler E; Vasudevan A; Wang Y; Ogale S
Cancer Treat Res Commun; 2022; 31():100522. PubMed ID: 35189530
[TBL] [Abstract][Full Text] [Related]
19. Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities.
Gutierrez ME; Choi K; Lanman RB; Licitra EJ; Skrzypczak SM; Pe Benito R; Wu T; Arunajadai S; Kaur S; Harper H; Pecora AL; Schultz EV; Goldberg SL
Clin Lung Cancer; 2017 Nov; 18(6):651-659. PubMed ID: 28479369
[TBL] [Abstract][Full Text] [Related]
20. Impact of Reflex EGFR/ ALK Testing on Time to Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Cheema PK; Menjak IB; Winterton-Perks Z; Raphael S; Cheng SY; Verma S; Muinuddin A; Freedman R; Toor N; Perera J; Anaka M; Victor JC
J Oncol Pract; 2017 Feb; 13(2):e130-e138. PubMed ID: 28029301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
